share_log

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test With Retail Launch

萬基遺傳擴大對家庭早期胎兒性別DNA測試的訪問,並在零售推出
GlobeNewswire ·  11/13 21:00

SneakPeek, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide

SneakPeek,首款可在六週使用的家庭早期胎兒性別測試,現在已經在全國800多家零售位置上市了

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they're having a girl or boy at-home as early as six weeks into pregnancy.

鹽湖城,2024年11月13日(GLOBE NEWSWIRE)-- 萬基遺傳公司(納斯達克: MYGN),遺傳測試和精準醫學領域的領導者,繼續爲父母提供更多產前測試的機會。 SneakPeek作爲1號婦產科醫生推薦的性別測試,準確率超過99%[1],現已在全國800多家零售店可購買。這款產品是首款在沃爾瑪門店貨架上銷售的產品,讓期待中的父母可以在懷孕六週時在家了解他們是在期待男孩還是女孩,從而大大擴展了機會。

According to a 2024 consumer survey, 82% of expectant parents want to know the baby's sex before delivery, and the majority – two to one[2] – said they would prefer to buy a test in-store vs. ordering online.[3] Today's expecting parents want to know fetal sex sooner than ever, for preparedness, naming, nursery and registries, as well as bonding and reduced stress.

根據2024年的一項消費者調查,82%的期待中的父母希望在分娩前知道寶寶的性別,大多數-兩比一[2]--表示他們更願意在店內購買測試,而不是線上下單[3]。今天的準父母希望儘早了解胎兒的性別,以備萬全,取名,裝修和註冊信息,以及加強親子關係和減少壓力。

"Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it," said Melissa Gonzales, president of women's health, Myriad Genetics. "By expanding access of the SneakPeek test through national retail partners, we're making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood."

"Our commitment to supporting new families is about providing trusted, affordable and accessible solutions that empower expectant parents with information when and where they want it," said Melissa Gonzales, president of women's health, Myriad Genetics. "By expanding access of the SneakPeek test through national retail partners, we're making it easier for more families to experience the meaningful moment of gender discovery and plan and prepare for parenthood."

The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand's new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby's gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over 99% accuracy in detecting a baby's gender as early as 6 weeks into pregnancy, clinically proven by peer-reviewed, published scientific studies.

The retail launch kicks off a product rebrand, new packaging design, and a website centered on the moment of gender discovery as the first key moment of parental bonding with a baby, which are scheduled for 2025. The brand's new tagline - Plan for Joy - celebrates the magical moments of joy and connection amidst all the challenges of pregnancy. Learning your baby's gender is one of the most exciting parts of pregnancy, and the SneakPeek test helps make that possible. SneakPeek is the only at-home test with over 99% accuracy in detecting a baby's gender as early as 6 weeks into pregnancy, clinically proven by peer-reviewed, published scientific studies.

Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor's offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek's parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.

Since 2015, the SneakPeek test has offered expectant families an easy and convenient non-invasive test available to order online and via doctor's offices to learn the sex of their baby. In 2022, Myriad Genetics acquired SneakPeek's parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.

How the Test Works
The retail test kit includes the patented SneakPeek Snap device, which is placed on the user's upper arm to nearly painlessly collect a blood sample with the simple press of a button. The sample is then mailed to the SneakPeek laboratory in the included, postage-paid envelope. Test results are delivered as early as the same day the sample is received through a celebratory text message and email.

測試的工作原理
零售測試套件包括專利的SneakPeek Snap設備,該設備被放置在用戶的上臂上,通過簡單按下一個按鈕幾乎無痛地收集血樣。 然後將樣本通過隨附的預付郵件信封郵寄到SneakPeek實驗室。 測試結果將在收到樣本的當天通過慶祝性短信和電子郵件發送。

The SneakPeek test is now available in Walmart, Walgreens and CVS stores. Click here to find a store near you.

SneakPeek測試現在可在沃爾瑪、沃爾格林和CVS商店購買。 點擊此處查找您附近的商店。

About SneakPeek
Through the SneakPeek test, Myriad Genetics is on a mission to make DNA-based prenatal information affordable and accessible for all families. For more information, visit sneakpeektest.com and follow the brand on Instagram and Facebook.

關於SneakPeek
通過SneakPeek測試,萬基遺傳正在致力於使基於DNA的產前信息對所有家庭都能負擔得起並易於獲取。欲了解更多信息,請訪問 sneakpeektest.com 並關注該品牌 包括提供反映我們世界多樣性的創新臨床試驗,並努力確保我們的藥品具有可擴展性和可負擔性。Facebook.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .

關於Myriad Genetics
萬基遺傳是一家領先的基因檢測和精準醫學公司,致力於推進所有人的健康和福祉。萬基遺傳開發並提供基因檢測,幫助評估發病風險或疾病進展,並指導治療決策,涉及醫療專業領域的基因洞察可以顯著改善患者護理,並降低醫療保健成本。欲了解更多信息,請訪問。

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company expects that SneakPeek's expansion into retailers in the United States will improve the products affordability and accessibility so that the test may be available to many more families who want to learn the sex of their baby at-home as early as six weeks into pregnancy and that a product rebrand, new packaging design, and a website centered on the moment of gender discovery are scheduled for launch in 2025. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

免責聲明
本新聞稿包含《1995年私人證券訴訟改革法案》的「前瞻性聲明」,其中包括公司預計SneakPeek進入美國零售商將提高產品的價格實惠性和可及性,從而使該測試可供更多希望在懷孕六週時就能在家了解寶寶性別的家庭,而且計劃於2025年推出產品重新品牌、新包裝設計以及以性別發現時刻爲中心的網站。這些「前瞻性聲明」是管理層針對今日後事的期望,並受到已知和未知風險和不確定性的影響,可能導致實際結果、狀況和事件與預期有實質和不利的不同。這些因素包括公司在美國證券交易委員會向美國證券交易委員會提交的風險描述中所描述的風險,包括公司於2024年2月28日提交的年度報告表格10-k,以及公司在不時提交的季度報告表格10-Q或當前報告表格8-k中針對這些風險因素的任何更新。Myriad公司無需且明確否認有義務更新或更改任何前瞻性聲明,除非法律要求。

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

投資者聯繫
馬特·斯卡洛
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com

媒體聯繫
Glenn Farrell
(385) 318-3718
PR@myriad.com

[1] In a 2021 laboratory test, SneakPeek accurately determined fetal sex in 99.02% of 102 pregnant women using the Snap device at 8-15 weeks gestational age. In a separate published study run in 2021, fetal sex was accurately determined in 100% of 134 pregnant women at 7 weeks gestational age. In a 2022 scientific study, SneakPeek accurately determined fetal sex for 100% of 103 women at 6 weeks gestational age.
[2] Gateway Genomics Research, August 2022; n=200.
[3] January 2024 Padilla Newsmaker Online Survey of 1,000 women age 21-45 who are trying to conceive, pregnant or have been pregnant.

[1] 在2021年的實驗室測試中,SneakPeek在孕8-15周的102名孕婦中使用Snap設備準確地確定了胎兒性別,準確率爲99.02%。另一項2021年發表的研究表明,在孕7周的134名孕婦中,胎兒性別被準確確定。在2022年的科學研究中,SneakPeek在孕6周的103名女性中準確確定了胎兒性別。
[2] Gateway Genomics研究,2022年8月;n=200。
[3] 2024年1月Padilla Newsmaker在線調查涉及1000名21-45歲的婦女,她們正在嘗試懷孕、懷孕或曾懷孕。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論